The preventative effects of statin on lung cancer development in patients with idiopathic pulmonary fibrosis using the National Health Insurance Service Database in Korea
- PMID: 38478558
- PMCID: PMC10936809
- DOI: 10.1371/journal.pone.0299484
The preventative effects of statin on lung cancer development in patients with idiopathic pulmonary fibrosis using the National Health Insurance Service Database in Korea
Abstract
Little is known about the effect of statin use in lung cancer development in idiopathic pulmonary fibrosis (IPF). We analyzed the database of the National Health Insurance Service to further investigate the clinical impacts of statin on lung cancer development and overall survival (OS) in IPF patients. The analysis included 9,182 individuals diagnosed with IPF, of which 3,372 (36.7%) were statin users. Compared to statin non-users, the time from diagnosis of IPF to lung cancer development and OS were longer in statin users in IPF patients. In Cox proportional hazard regression models, higher statin compliance, statin use, and being female had an inverse association with lung cancer risk, while older age at diagnosis of IPF and smoking history were associated with higher risk of lung cancer in IPF patients. For OS, statin use, female sex, higher physical activity frequency, and diabetes were associated with longer survival. In contrast, older age at diagnosis of IPF and smoking history were associated with shorter OS in IPF patients. These data from a large population indicate that statin had an independent protective association with lung cancer development and mortality in IPF patients.
Copyright: © 2024 Lee et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Similar articles
-
Association between statin use and the risk for idiopathic pulmonary fibrosis and its prognosis: a nationwide, population-based study.Sci Rep. 2024 Apr 2;14(1):7805. doi: 10.1038/s41598-024-58417-9. Sci Rep. 2024. PMID: 38565856 Free PMC article.
-
Risk factors and clinical characteristics of lung cancer in idiopathic pulmonary fibrosis: a retrospective cohort study.BMC Pulm Med. 2019 Aug 14;19(1):149. doi: 10.1186/s12890-019-0905-8. BMC Pulm Med. 2019. PMID: 31412851 Free PMC article.
-
Association between the use of statins and risk of interstitial lung disease/idiopathic pulmonary fibrosis: time-dependent analysis of population-based nationwide data.Eur Respir J. 2023 Jul 7;62(1):2300291. doi: 10.1183/13993003.00291-2023. Print 2023 Jul. Eur Respir J. 2023. PMID: 37202155
-
Progress of Statin Therapy in the Treatment of Idiopathic Pulmonary Fibrosis.Oxid Med Cell Longev. 2022 Mar 19;2022:6197219. doi: 10.1155/2022/6197219. eCollection 2022. Oxid Med Cell Longev. 2022. Retraction in: Oxid Med Cell Longev. 2024 Jan 9;2024:9830469. doi: 10.1155/2024/9830469 PMID: 35345828 Free PMC article. Retracted. Review.
-
Idiopathic pulmonary fibrosis will increase the risk of lung cancer.Chin Med J (Engl). 2014;127(17):3142-9. Chin Med J (Engl). 2014. PMID: 25189961 Review.
Cited by
-
The Association between Dyslipidemia and Pulmonary Diseases.J Atheroscler Thromb. 2024 Sep 1;31(9):1249-1259. doi: 10.5551/jat.RV22021. Epub 2024 Jul 12. J Atheroscler Thromb. 2024. PMID: 39010219 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical